Cargando…
Treatment of primary testicular diffuse large B cell lymphoma without prophylactic intrathecal chemotherapy: a single center experience
BACKGROUND: Primary testicular diffuse large B-cell lymphoma (DLBCL) is a rare but aggressive extranodal lymphoma, and its relapse in the central nervous system (CNS) is a major concern during treatment. Despite this, the role of intrathecal prophylaxis in primary testicular DLBCL remains controvers...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4188782/ https://www.ncbi.nlm.nih.gov/pubmed/25325036 http://dx.doi.org/10.5045/br.2014.49.3.170 |
_version_ | 1782338269983277056 |
---|---|
author | Kim, Jeongseok Yoon, Dok Hyun Park, Inkeun Kim, Shin Park, Jung Sun Lee, Sang-Wook Huh, Jooryung Park, Chan-Sik Suh, Cheolwon |
author_facet | Kim, Jeongseok Yoon, Dok Hyun Park, Inkeun Kim, Shin Park, Jung Sun Lee, Sang-Wook Huh, Jooryung Park, Chan-Sik Suh, Cheolwon |
author_sort | Kim, Jeongseok |
collection | PubMed |
description | BACKGROUND: Primary testicular diffuse large B-cell lymphoma (DLBCL) is a rare but aggressive extranodal lymphoma, and its relapse in the central nervous system (CNS) is a major concern during treatment. Despite this, the role of intrathecal prophylaxis in primary testicular DLBCL remains controversial. METHODS: We retrospectively reviewed the medical records of 14 patients with primary testicular DLBCL diagnosed between November 2000 and June 2012, and analyzed the CNS relapse rate in patients treated without intrathecal prophylaxis. Survival curves were estimated using the Kaplan-Meier method. RESULTS: The median age at diagnosis was 57 years (range, 41-79 years). Unilateral testicular involvement was observed in 13 patients. Nine patients had stage I, 1 had stage II, and 4 had stage IV disease. The international prognostic index was low or low-intermediate risk in 12 patients and high-intermediate risk in 2 patients. Thirteen patients underwent orchiectomy. All the patients received systemic chemotherapy without intrathecal prophylaxis, and prophylactic radiotherapy was administered to the contralateral testis in 12 patients. The median follow-up period of surviving patients was 39 months (range, 10-139 months). Median overall survival was not reached and the median progression-free survival was 3.8 years. Four patients experienced relapse, but CNS relapse was observed in only one patient (7.1%) with stage IV disease, 27 months after a complete response. CONCLUSION: Even without intrathecal prophylaxis, the rate of relapse in the CNS was lower in the Korean patients with primary testicular DLBCL compared to prior reports. |
format | Online Article Text |
id | pubmed-4188782 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis |
record_format | MEDLINE/PubMed |
spelling | pubmed-41887822014-10-16 Treatment of primary testicular diffuse large B cell lymphoma without prophylactic intrathecal chemotherapy: a single center experience Kim, Jeongseok Yoon, Dok Hyun Park, Inkeun Kim, Shin Park, Jung Sun Lee, Sang-Wook Huh, Jooryung Park, Chan-Sik Suh, Cheolwon Blood Res Original Article BACKGROUND: Primary testicular diffuse large B-cell lymphoma (DLBCL) is a rare but aggressive extranodal lymphoma, and its relapse in the central nervous system (CNS) is a major concern during treatment. Despite this, the role of intrathecal prophylaxis in primary testicular DLBCL remains controversial. METHODS: We retrospectively reviewed the medical records of 14 patients with primary testicular DLBCL diagnosed between November 2000 and June 2012, and analyzed the CNS relapse rate in patients treated without intrathecal prophylaxis. Survival curves were estimated using the Kaplan-Meier method. RESULTS: The median age at diagnosis was 57 years (range, 41-79 years). Unilateral testicular involvement was observed in 13 patients. Nine patients had stage I, 1 had stage II, and 4 had stage IV disease. The international prognostic index was low or low-intermediate risk in 12 patients and high-intermediate risk in 2 patients. Thirteen patients underwent orchiectomy. All the patients received systemic chemotherapy without intrathecal prophylaxis, and prophylactic radiotherapy was administered to the contralateral testis in 12 patients. The median follow-up period of surviving patients was 39 months (range, 10-139 months). Median overall survival was not reached and the median progression-free survival was 3.8 years. Four patients experienced relapse, but CNS relapse was observed in only one patient (7.1%) with stage IV disease, 27 months after a complete response. CONCLUSION: Even without intrathecal prophylaxis, the rate of relapse in the CNS was lower in the Korean patients with primary testicular DLBCL compared to prior reports. Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2014-09 2014-09-25 /pmc/articles/PMC4188782/ /pubmed/25325036 http://dx.doi.org/10.5045/br.2014.49.3.170 Text en © 2014 Korean Society of Hematology http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Kim, Jeongseok Yoon, Dok Hyun Park, Inkeun Kim, Shin Park, Jung Sun Lee, Sang-Wook Huh, Jooryung Park, Chan-Sik Suh, Cheolwon Treatment of primary testicular diffuse large B cell lymphoma without prophylactic intrathecal chemotherapy: a single center experience |
title | Treatment of primary testicular diffuse large B cell lymphoma without prophylactic intrathecal chemotherapy: a single center experience |
title_full | Treatment of primary testicular diffuse large B cell lymphoma without prophylactic intrathecal chemotherapy: a single center experience |
title_fullStr | Treatment of primary testicular diffuse large B cell lymphoma without prophylactic intrathecal chemotherapy: a single center experience |
title_full_unstemmed | Treatment of primary testicular diffuse large B cell lymphoma without prophylactic intrathecal chemotherapy: a single center experience |
title_short | Treatment of primary testicular diffuse large B cell lymphoma without prophylactic intrathecal chemotherapy: a single center experience |
title_sort | treatment of primary testicular diffuse large b cell lymphoma without prophylactic intrathecal chemotherapy: a single center experience |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4188782/ https://www.ncbi.nlm.nih.gov/pubmed/25325036 http://dx.doi.org/10.5045/br.2014.49.3.170 |
work_keys_str_mv | AT kimjeongseok treatmentofprimarytesticulardiffuselargebcelllymphomawithoutprophylacticintrathecalchemotherapyasinglecenterexperience AT yoondokhyun treatmentofprimarytesticulardiffuselargebcelllymphomawithoutprophylacticintrathecalchemotherapyasinglecenterexperience AT parkinkeun treatmentofprimarytesticulardiffuselargebcelllymphomawithoutprophylacticintrathecalchemotherapyasinglecenterexperience AT kimshin treatmentofprimarytesticulardiffuselargebcelllymphomawithoutprophylacticintrathecalchemotherapyasinglecenterexperience AT parkjungsun treatmentofprimarytesticulardiffuselargebcelllymphomawithoutprophylacticintrathecalchemotherapyasinglecenterexperience AT leesangwook treatmentofprimarytesticulardiffuselargebcelllymphomawithoutprophylacticintrathecalchemotherapyasinglecenterexperience AT huhjooryung treatmentofprimarytesticulardiffuselargebcelllymphomawithoutprophylacticintrathecalchemotherapyasinglecenterexperience AT parkchansik treatmentofprimarytesticulardiffuselargebcelllymphomawithoutprophylacticintrathecalchemotherapyasinglecenterexperience AT suhcheolwon treatmentofprimarytesticulardiffuselargebcelllymphomawithoutprophylacticintrathecalchemotherapyasinglecenterexperience |